Deals: Page 87
-
Companies collaborate to fight multidrug-resistant pathogens
A new diagnostic test is available in Europe and coming to the U.S., but that's just the first step.
By Nicole Gray • June 22, 2014 -
J&J rachets up R&D through 12 new alliances
The company has many collaborations underway.
By Nicole Gray • June 20, 2014 -
Pfizer expands immuno-oncology research through Cellectics parnership
Pfizer is expanding oncology research by collaborating with Cellectics, which brings a unique immuno-oncology research platform to the partnership.
By Nicole Gray • June 19, 2014 -
Pfizer expands research capacity with Cambridge, MA location
The firm is setting up a mega-research facility, bringing together industry, academic and the hospital system to collaborate on therapeutic innovation.
By Nicole Gray • June 18, 2014 -
JNJ partners with Viiv to create new combo HIV drug
The medication could end up rivaling Atripla.
By Nicole Gray • June 17, 2014 -
Sanofi, Medtronic team up to offer options for diabetes patients
The new partnership focuses on innovative drug-device breakthroughs.
By Nicole Gray • June 17, 2014 -
Medtronic buying Ireland-based Covidien
The merger will make Medtronic a mega-medical-device company.
By Nicole Gray • June 16, 2014 -
NICE reverses stance on skin cancer treatment after reviewing new survival data
The panel changed its decision of four months ago based on positive survival data extending out three years.
By Nicole Gray • June 16, 2014 -
Parion, Santen bring dry eye drug to Asian markets
The drug has a novel mode of action and will help Parion build an Asian distribution network with a new partner.
By Nicole Gray • June 13, 2014 -
X-Chem, Pfizer team up on orphan drug development
The collaboration pairs two companies that are powerful in different ways.
By Nicole Gray • June 13, 2014 -
Lilly's Cyramza fails in phase III liver cancer trials, but sees a way forward
Although the drug failed to show statistical results for survival advantage in patients with advanced liver cancer, there were some meaningful results.
By Nicole Gray • June 13, 2014 -
AstraZeneca breathes new life into its respiratory portfolio
The company has acquired rights to a drug developed by Synairgen and is reporting positive phase II results on its psoriatric arthritis drug.
By Nicole Gray • June 13, 2014 -
Valeant tries again and Allergan says 'no'
Same question, same answer. Allergan contends that Valeant's increased offer still undervalues the company.
By Nicole Gray • June 11, 2014 -
Dendreon faces large debt payment as CEO departs
For the company, the combination of low Provenge sales and high debt has been challenging, leading to speculation about its future.
By Nicole Gray • June 11, 2014 -
GelStat gets medical marijuana foothold with Mastix Medica acquisition
The acquisition will bolster Gelstat's weight-loss chewing gum product line and allow the company to move into the high CBD/low THC market.
By Nicole Gray • June 10, 2014 -
South-Korea based Cho-A Pharma partners with Manchester United
Given the soccer team's fan base throughout Korea and Vietnam, this partnership represents a path to increase interest in Cho-A Pharm's nutritional and OTC products.
By Nicole Gray • June 10, 2014 -
Merck bets big on hepatitis C market with Idenix purchase
The products being developed by the two firms are different types of drugs, with different mechanisms of action, but they all are oral and interferon-free.
By Nicole Gray • June 10, 2014 -
Deep Dive
AstraZeneca ties its future to a promising drug pipeline
The firm predicts a nearly $20 billion increase in revenues by 2023, as it continues to develop small-molecule and biologics-based therapies for the treatment of various cancers.
By Nicole Gray • June 8, 2014 -
BMS and Indian CRO extend drug discovery contract
Eight years of collaboration between the two companies has produced six drug candidates.
By Nicole Gray • June 5, 2014 -
Bayer, Orion partnering to develop prostate cancer drug
Bayer is trying to build a strong portfolio in this therapeutic area--and is off to a good start with Xofigo, which was approved last year.
By Nicole Gray • June 5, 2014 -
Bayer CEO lays out departure plans
Even pharmaceutical executives grapple with work-life balance....Marijn Dekkers is planning to leave his chief executive officer position at Bayer by December 2016.
By Nicole Gray • June 4, 2014 -
Valeant and Pershing Square initiate hostile takeover of Allergan
After increasing the offer by about 20%, the next move is to go straight to the shareholders.
By Nicole Gray • June 2, 2014 -
Hikma Pharmaceuticals to acquire Bedford
Two large acquisitions in less than four years has put UK-based Hikma on the map. Its latest acquisition may also include a manufacturing facility.
By Nicole Gray • May 30, 2014 -
Pfizer expands OTC portfolio with launch of OTC Nexium 24HR
The launch marks the fourth therapeutic area in which the company has an OTC presence. Pfizer acquired rights to Nexium from AstraZeneca in 2012.
By Nicole Gray • May 29, 2014 -
BMS dives into the immunooncology fray with CytomX collaboration
Other companies, including Merck, AstraZeneca and Pfizer are also heavily involved in immunooncology. Data highlights from this research will be reported at ASCO.
By Nicole Gray • May 28, 2014
Previous
